Cancer Immunotherapy Drug Discovery Outsourcing Market – Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Drug Type (Monoclonal Antibodies, Immunomodulators, Cancer Vaccines and Oncolytic Viral Therapy, others), By Service Type (Target Identification and Validation, Lead Screening and Characterization, Cell-based Assays), by Cancer Type (Lung, Breast, Colorect
Published Date: November - 2024 | Publisher: MIR | No of Pages: 320 | Industry: Healthcare | Format: Report available in PDF / Excel Format
View Details Buy Now 2890 Download Sample Ask for Discount Request CustomizationCancer Immunotherapy Drug Discovery Outsourcing Market – Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Drug Type (Monoclonal Antibodies, Immunomodulators, Cancer Vaccines and Oncolytic Viral Therapy, others), By Service Type (Target Identification and Validation, Lead Screening and Characterization, Cell-based Assays), by Cancer Type (Lung, Breast, Colorect
| Forecast Period | 2024-2028 |
| Market Size (2022) | USD1.05 billion |
| CAGR (2023-2028) | 8.70% |
| Fastest Growing Segment | Target Identification |
| Largest Market | North America |
Market Overview
Global Cancer Immunotherapy Drug Discovery Outsourcing Market was valued at USD 1.05 billion in 2022 and is anticipated to witness an impressive growth in the forecast period with a CAGR of 8.70% through 2028.
Key Market Drivers
Increasing Patient Demand and Awareness
Patients today have greater access to information about cancer treatment options, including immunotherapy, through the internet, social media, and patient advocacy groups. This increased awareness leads patients to seek out the latest and most promising therapies. Many patients with cancer are seeking innovative and more effective treatments, especially when traditional therapies have not yielded satisfactory results or are associated with significant side effects. Immunotherapies represent a promising and less toxic approach. Awareness about the concept of personalized medicine has grown. Patients are increasingly aware that cancer immunotherapies can be tailored to their specific genetic and molecular profiles, making them more effective and less likely to cause adverse effects. Patients are more willing to participate in clinical trials, as they recognize the potential benefits of receiving cutting-edge treatments. Clinical trials often rely on outsourcing services for various aspects, including patient recruitment and data management. Patient advocacy groups and organizations dedicated to specific types of cancer actively promote awareness about the latest treatments, including immunotherapies. They often collaborate with researchers and pharmaceutical companies, indirectly contributing to the growth of outsourcing services. As patients become more informed, they engage in discussions with their healthcare providers about treatment options, including immunotherapy. This dialogue drives interest in these therapies and encourages healthcare professionals to explore outsourcing for the latest treatments.
Personal success stories shared by other patients who have benefited from immunotherapy can influence a patient's decision to explore these treatments. Such stories often lead to increased inquiries about immunotherapies and clinical trials. Patients and their families, driven by a desire for better treatment options, often support cancer research funding and philanthropic efforts. These contributions can indirectly lead to an increase in cancer immunotherapy research and, by extension, outsourcing services. Patients in various regions and socioeconomic backgrounds are demanding improved access to advanced treatments, including immunotherapies. Outsourcing can help bridge the gap by making these treatments more widely found at. Patient demand and awareness are not limited to a single geographic region. These factors are increasingly shaping the global landscape of cancer immunotherapy research and outsourcing. This factor will help in the development of the
Technological Advancements
Next-Generation Sequencing (NGS) has revolutionized genomics by enabling the rapid and cost-effective sequencing of large volumes of DNA and RNA. This technology is crucial for identifying genetic mutations and biomarkers in cancer patients, which is essential for the development of personalized immunotherapies. High-Throughput Screening (HTS) technologies allow the rapid testing of thousands of drug compounds to identify potential immunotherapeutic agents. This accelerates the drug discovery process by identifying promising candidates for further development. Cryo-Electron Microscopy (Cryo-EM) is a powerful imaging technique that has advanced our understanding of the structural biology of proteins and their interactions. It has been instrumental in studying the structures of immune checkpoint proteins and antibodies, which are crucial for immunotherapy development. Single-cell RNA sequencing and mass cytometry techniques enable researchers to analyze individual cells within a tumor or immune microenvironment. This level of detail is essential for understanding the heterogeneity of tumors and the immune response.
AI and machine learning algorithms are used to analyze large datasets, predict potential drug candidates, and identify biomarkers. These technologies can speed up drug discovery and improve the accuracy of target identification. CRISPR-Cas9 technology allows for precise and targeted genetic modifications. It is used to develop preclinical models, validate potential drug targets, and study the role of specific genes in cancer and the immune response. Advances in biotechnology have led to the development of more sophisticated monoclonal antibodies, bispecific antibodies, and other biologics used in cancer immunotherapy. Technologies for vaccine development, such as mRNA vaccine platforms (similar to the ones used in COVID-19 vaccines), are being explored for their potential in cancer immunotherapy.
These technologies allow for the detailed analysis of immune cell populations and their functional characteristics in response to cancer. They help in identifying potential targets for immunotherapies. Liquid biopsies, which involve the analysis of blood or other body fluids, provide a non-invasive way to monitor tumor mutations and immune response markers, aiding in patient selection and monitoring of therapy responses. Managing and analyzing the vast amount of data generated in cancer immunotherapy research is made possible through big data analytics tools, which help in identifying patterns and insights. Improved cell culture methods, including organoids and patient-derived xenograft models, enable more accurate testing of potential therapies before moving to clinical trials. This factor will pace up the demand of the
Emerging Cancer Types
Emerging cancer types often lack effective treatment options, leading to unmet medical needs. Immunotherapy offers a promising avenue for addressing these needs, and the outsourcing of drug discovery services becomes crucial in developing innovative therapies. Advances in genomics and molecular biology have led to the discovery of specific genetic mutations and biomarkers associated with rare or newly recognized cancer types. Outsourcing services play a role in identifying these targets and developing tailored immunotherapies.
Patients and advocacy groups dedicated to less common cancers actively raise awareness and support research efforts. This advocacy can drive research funding and partnerships, increasing the demand for outsourcing services to accelerate drug development. The concept of personalized or precision medicine is especially relevant for emerging cancer types, where the genetic and molecular profiles of tumors vary widely. Outsourcing helps develop therapies tailored to individual patients. Regulatory agencies may provide incentives or expedited pathways for the development of treatments for rare or orphan diseases, including rare cancer types. This can encourage pharmaceutical companies to invest in research and outsourcing.
Collaborations between pharmaceutical companies, academic institutions, and outsourcing firms can bring together specialized expertise in rare cancer types, ensuring that innovative solutions are developed. Outsourcing services enable access to global expertise and resources, allowing for a wider and more diverse approach to addressing rare and emerging cancer types. The design and management of clinical trials for rare cancers requires expertise in patient recruitment, data analysis, and regulatory compliance. Outsourcing is often used to optimize these processes. While individual rare cancer markets may be smaller, the cumulative market potential for emerging cancer types can be significant. Pharmaceutical companies recognize this growth potential and invest in research and outsourcing services. The introduction of immunotherapies for rare cancers expands the range of therapeutic options found at to patients, providing hope and improving the quality of life for those affected. This factor will accelerate the demand of the Global Cancer Immunotherapy Drug Discovery Outsourcing Market.
Key Market Challenges
Quality Control and Standardization
The drug discovery process for cancer immunotherapies is complex and continually evolving. Ensuring consistent quality and standards across different stages of this process, from target identification to clinical trials, is a significant challenge. Outsourcing projects often involve multiple sites, including research organizations, pharmaceutical companies, and contract r
Long Development Timelines
Cancer immunotherapy drug discovery involves a multifaceted process, from target identification to clinical trials. Each step requires rigorous testing and validation, contributing to lengthy timelines. Preclinical research, including target identification, biomarker discovery, and initial drug testing, can be time-consuming. The need for extensive validation and optimization of potential therapies adds to the timeline. Clinical trials, which are a critical stage in drug development, are inherently time-consuming. These trials often consist of multiple phases, including safety and efficacy assessments, and each phase requires a substantial amount of time. Navigating the regulatory approval process, which varies by region, adds time to drug development. Ensuring compliance with regulatory standards and addressing regulatory queries can lead to delays. Patient recruitment for clinical trials, especially in the case of rare cancers, can be a major bottleneck. Finding and enrolling eligible participants often takes longer than anticipated. The analysis and reporting of clinical trial data are time-intensive tasks. Ensuring the accuracy and completeness of data adds to the timeline before a therapy can progress to the next phase or regulatory submission.
Key Market Trends
Increasing Research in Checkpoint Inhibitors
Checkpoint inhibitors, such as PD-1 and PD-L1 inhibitors, have demonstrated substantial clinical success in the treatment of various cancers, including melanoma, lung cancer, and more. This success has driven increased research and development in this area. Research is ongoing to explore the use of checkpoint inhibitors for a broader range of cancer types and stages. This expansion of indications requires extensive outsourcing services for clinical trial management and patient recruitment. Researchers are investigating combinations of checkpoint inhibitors with other immunotherapies, chemotherapy, targeted therapies, and radiation therapy. This approach requires extensive research and outsourcing support. Identifying predictive and prognostic biomarkers to guide the use of checkpoint inhibitors is a key focus of research. Outsourcing services play a critical role in biomarker discovery. The trend toward personalized medicine in cancer treatment emphasizes the need to identify which patients are most likely to benefit from checkpoint inhibitors. Outsourcing services contribute to this patient-centric approach.
Segmental Insights
Service Type Insights
In 2022, the Global Cancer Immunotherapy Drug Discovery Outsourcing Market largest share was held by target identification segment and is predicted to continue expanding over the coming years.
Drug Type Insights
In 2022, the Global Cancer Immunotherapy Drug Discovery Outsourcing Market largest share was held by monoclonal antibodies segment and is predicted to continue expanding over the coming years.
Cancer Type Insights
lung cancer
Regional Insights
The North America region dominates the Global Cancer Immunotherapy Drug Discovery Outsourcing Market in 2022. North America, particularly the United States and Canada, boasts advanced healthcare infrastructure and a well-established pharmaceutical and biotechnology industry. This infrastructure supports and accelerates drug discovery and development efforts. The region is home to numerous leading pharmaceutical and biotechnology companies, academic research institutions, and healthcare facilities that collaborate extensively on cancer immunotherapy research and development. North America has robust funding mechanisms for healthcare and life sciences research. This access to capital allows for increased investment in cancer immunotherapy drug discovery and outsourcing services. Regulatory agencies like the U.S. Food and Drug Administration (FDA) and Health Canada have extensive experience in evaluating and approving immunotherapy drugs. Their expertise facilitates smoother development and regulatory processes. The region attracts and retains top talent in fields like immunology, genetics, bioinformatics, and clinical research, which are crucial for cancer immunotherapy research and development.
Recent Developments
- In February 2023, Personalis,Inc., a prominent player in advanced genomics for precision oncology, hasannounced a new agreement with Moderna, Inc., a pioneering biotechnologycompany in the field of messenger RNA (mRNA) therapeutics and vaccines. Thisagreement extends the use of the Personalis NeXT Platform in upcoming clinicalstudies focused on mRNA-4157/V940, an investigational personalized cancervaccine jointly developed by Moderna and Merck (known as MSD outside of theUnited States and Canada). The NeXT Platform,previously employed in the Phase 2b clinical study of the vaccine candidate,will continue to be utilized. It serves the purpose of sequencing genomic dataderived from a patient's tumor sample. This sequencing is aimed at identifyingthe distinct genetic mutations that are most likely to elicit a customizedantitumor response.
- Personalis, Inc. is at theforefront of advanced cancer genomics, facilitating the development of the nextgeneration of precision cancer therapies and diagnostics. The Personalis NeXTPlatform is thoughtfully designed to adapt to the intricate and ever-evolvinglandscape of cancer. It equips biopharmaceutical clients and healthcarepractitioners with comprehensive information on all approximately 20,000 humangenes and the immune system, all derived from a single sample.
- In July 2021, Labcorpunveiled its plans for an expansion of its oncology offerings by acquiringOmniSeq, a trailblazer in solid tumor profiling utilizing next generationsequencing technologies and providing extensive pharmaceutical services toadvance drug development. This strategic move further strengthens Labcorp'sexpanding array of diagnostic tests and clinical trial prospects forindividuals grappling with cancer and the healthcare professionals dedicated totheir care. With the integration of OmniSeq, Labcorp enriches its oncology testlineup, which is tailored to harness cutting-edge scientific advancements andinsights from clinical and patient data, ultimately delivering precisesolutions for cancer and enhancing patient outcomes.
Key Market Players
- Covance, Inc.
- Horizon Discovery Group PLC
- Crown Bioscience, Inc.
- Promega Corporation
- HD Biosciences Co., Ltd.
- BPS Bioscience, Inc.
- Genscript Biotech Corporation
- DiscoverX Corporation
- Celentyx Ltd.
- ImmunXperts SA
| By Service Type | By Drug Type | By Cancer Type | By Region |
|
|
|
|
Report Scope
In this report, the Global Cancer Immunotherapy Drug Discovery Outsourcing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below
- Cancer Immunotherapy Drug Discovery Outsourcing Market, By Service Type
o
o
o
- Cancer Immunotherapy Drug Discovery Outsourcing Market, By Drug Type
o
o
o
o
- Cancer Immunotherapy Drug Discovery Outsourcing Market, By Cancer Type
o
o
o
o
o
o
- Cancer Immunotherapy Drug Discovery Outsourcing Market, By region
o
o
o
o
o
Competitive Landscape
Company Profiles
found at Customizations
Company Information
- Detailed analysis and profiling of additional market players (up to five).
Global Cancer Immunotherapy Drug Discovery Outsourcing Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at
FAQ'S
For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:
Within 24 to 48 hrs.
You can contact Sales team (sales@marketinsightsresearch.com) and they will direct you on email
You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.
Discounts are available.
Hard Copy